Analytical Data
-
Gene name
FGFR1OP
- Application
-
Alternative Names
FGFR1OP;FGFR1OP;FOP;Centrosomal Protein 43
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95684
-
Expression Region
1-399aa
-
AA Sequence
MAATAAAVVA EEDTELRDLL VQTLENSGVL NRIKAELRAA VFLALEEQEK VENKTPLVNE SLKKFLNTKD GRLVASLVAE FLQFFNLDFT LAVFQPETST LQGLEGRENL ARDLGIIEAE GTVGGPLLLE VIRRCQQKEK GPTTGEGALD LSDVHSPPKS PEGKTSAQTT PSKIPRYKGQ GKKKTSGQKA GDKKANDEAN QSDTSVSLSE PKSKSSLHLL SHETKIGSFL SNRTLDGKDK AGLCPDEDDM EGDSFFDDPI PKPEKTYGLR KEPRKQAGSL ASLSDAPPLK SGLSSLAGAP SLKDSESKRG NTVLKDLKLI SDKIGSLGLG TGEDDDYVDD FNSTSHRSEK SEISIGEEIE EDLSVEIDDI NTSDKLDDLT QDLTVSQLSD VADYLEDVA
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FGFR1OP (FGFR1 Oncogene Partner) is a protein that has garnered significant attention in the fields of cancer research and molecular biology due to its involvement in various cellular processes and oncogenic pathways. It was initially identified as a fusion partner for the FGFR1 gene in certain hematological malignancies, suggesting its role in tumorigenesis. FGFR1OP plays a crucial role in the regulation of cellular growth, differentiation, and survival, making it a potential target for therapeutic intervention. Research has shown that aberrant expression or mutation of FGFR1OP can lead to dysregulation of signaling pathways associated with cancer progression. Understanding the molecular mechanisms underlying FGFR1OP’s function and its interactions with other oncogenic proteins is essential for elucidating its role in neoplastic transformation. Furthermore, examining FGFR1OP’s involvement in signal transduction pathways may provide insights into new treatment options for cancers exhibiting FGFR1 alterations. Given the complexity of its interactions and the clinical implications of FGFR1OP dysregulation, ongoing studies are aimed at developing FGFR1OP-targeted therapies, with the hope of improving patient outcomes in specific cancer types.











